Tags

Type your tag names separated by a space and hit enter

Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.
Int J Mol Sci. 2021 Feb 13; 22(4)IJ

Abstract

Cannabidiol (CBD) is the most abundant non-psychoactive component of cannabis; it displays a very low affinity for cannabinoid receptors, facilitates endocannabinoid signaling by inhibiting the hydrolysis of anandamide, and stimulates both transient receptor potential vanilloid 1 and 2 and serotonin type 1A receptors. Since CBD interacts with a wide variety of molecular targets in the brain, its therapeutic potential has been investigated in a number of neuropsychiatric diseases, including anxiety and mood disorders. Specifically, CBD has received growing attention due to its anxiolytic and antidepressant properties. As a consequence, and given its safety profile, CBD is considered a promising new agent in the treatment of anxiety and mood disorders. However, the exact molecular mechanism of action of CBD still remains unknown. In the present preclinical review, we provide a summary of animal-based studies that support the use of CBD as an anxiolytic- and antidepressant-like compound. Next, we describe neuropharmacological evidence that links the molecular pharmacology of CBD to its behavioral effects. Finally, by taking into consideration the effects of CBD on DNA methylation, histone modifications, and microRNAs, we elaborate on the putative role of epigenetic mechanisms in mediating CBD's therapeutic outcomes.

Authors+Show Affiliations

Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, 11364 Stockholm, Sweden. Center for Molecular Medicine, L8:00, Karolinska University Hospital, 17176 Stockholm, Sweden.Division of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy.Division of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy.Pharmacology Unit, School of Pharmacy, University of Camerino, 62032 Camerino, Italy.Division of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy. CNR Institute of Neuroscience-Cagliari, National Research Council, 09042 Cagliari, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33668469

Citation

Melas, Philippe A., et al. "Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights From Preclinical Research." International Journal of Molecular Sciences, vol. 22, no. 4, 2021.
Melas PA, Scherma M, Fratta W, et al. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. Int J Mol Sci. 2021;22(4).
Melas, P. A., Scherma, M., Fratta, W., Cifani, C., & Fadda, P. (2021). Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. International Journal of Molecular Sciences, 22(4). https://doi.org/10.3390/ijms22041863
Melas PA, et al. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights From Preclinical Research. Int J Mol Sci. 2021 Feb 13;22(4) PubMed PMID: 33668469.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. AU - Melas,Philippe A, AU - Scherma,Maria, AU - Fratta,Walter, AU - Cifani,Carlo, AU - Fadda,Paola, Y1 - 2021/02/13/ PY - 2021/01/27/received PY - 2021/02/08/revised PY - 2021/02/09/accepted PY - 2021/3/6/entrez PY - 2021/3/7/pubmed PY - 2021/4/16/medline KW - 5-HT1A receptors KW - CB1 receptors KW - DNA methylation KW - TRPV1 receptors KW - anxiety KW - cannabidiol KW - depression KW - epigenetics KW - histone modifications KW - miRNA JF - International journal of molecular sciences JO - Int J Mol Sci VL - 22 IS - 4 N2 - Cannabidiol (CBD) is the most abundant non-psychoactive component of cannabis; it displays a very low affinity for cannabinoid receptors, facilitates endocannabinoid signaling by inhibiting the hydrolysis of anandamide, and stimulates both transient receptor potential vanilloid 1 and 2 and serotonin type 1A receptors. Since CBD interacts with a wide variety of molecular targets in the brain, its therapeutic potential has been investigated in a number of neuropsychiatric diseases, including anxiety and mood disorders. Specifically, CBD has received growing attention due to its anxiolytic and antidepressant properties. As a consequence, and given its safety profile, CBD is considered a promising new agent in the treatment of anxiety and mood disorders. However, the exact molecular mechanism of action of CBD still remains unknown. In the present preclinical review, we provide a summary of animal-based studies that support the use of CBD as an anxiolytic- and antidepressant-like compound. Next, we describe neuropharmacological evidence that links the molecular pharmacology of CBD to its behavioral effects. Finally, by taking into consideration the effects of CBD on DNA methylation, histone modifications, and microRNAs, we elaborate on the putative role of epigenetic mechanisms in mediating CBD's therapeutic outcomes. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/33668469/Cannabidiol_as_a_Potential_Treatment_for_Anxiety_and_Mood_Disorders:_Molecular_Targets_and_Epigenetic_Insights_from_Preclinical_Research_ DB - PRIME DP - Unbound Medicine ER -